Related Experiment Videos
Platelet glycoprotein IIb/IIIa receptor antagonists
1Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F25, Cleveland, OH 44195, USA.
Expert Opinion on Pharmacotherapy
|March 16, 2001
Summary
Platelet glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors reduce ischemic events in acute coronary syndromes and after interventions. Oral GP IIb/IIIa inhibitors show disappointing results, but research continues.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Platelet thrombus formation is key in acute coronary syndromes (ACS) and post-intervention vessel closure.
- This understanding led to the development of platelet glycoprotein IIb/IIIa (GP IIb/IIIa) inhibitors.
Purpose of the Study:
- To review the efficacy and safety of GP IIb/IIIa inhibitors in ACS and coronary interventions.
- To discuss ongoing research and unresolved issues regarding their use.
Main Methods:
- Review of clinical trials and studies on parenteral and oral GP IIb/IIIa inhibitors.
- Analysis of safety data, including hemorrhagic complications and thrombocytopenia.
Main Results:
- Parenteral GP IIb/IIIa inhibitors consistently reduce ischemic endpoints in coronary interventions and ACS.
- Oral GP IIb/IIIa inhibitors have shown disappointing results in prolonged use.
- Combination therapy with fibrinolytic agents for ST-elevation myocardial infarction shows promise.
Conclusions:
- Parenteral GP IIb/IIIa inhibitors are effective and safe for ACS and coronary interventions.
- Further research is needed for oral agents, optimal dosing, duration, and adjunctive therapies.